Data / Medical devices / United States / Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc.: FDA-registered device maker in Malvern, PA, United States, 2 510(k) clearances
Fujirebio Diagnostics, Inc. is registered with the FDA (registration 2521625) in Malvern, PA, United States. It lists 20 device types. The FDA files 2 510(k) clearances under its listings, the newest dated May 16, 2025. 2 recall events name it as the recalling firm. Registered through 2026. FDA data exported November 2, 2026.
SpecStream is the live web data engine for teams and agents. It reads the FDA registration and listing, 510(k), PMA, recall and enforcement files from openFDA every week, and this page is that reading, joined by the FDA's own numbers. Ask for the makers of any device type in any country and new clearances, approvals and recalls arrive in your sheet, CRM, Slack or agent as the FDA publishes them.
- FDA registration number
- 2521625
- Address
- 201 Great Valley Parkway, Malvern, PA, United States, 19355
- Owner or operator
- Fujirebio Diagnostics, Inc. (10022860)
- Roles
- Contract manufacturer, Manufacturer, Manufacturer for export
- First device listed
- October 17, 2007
- Registered through
- 2026
- Brand names listed
- ADVIA Centaur XPT Cytokeratin Fragment 21-1 MCM (CYFRA MCM) - Siemens, ADVIA Centaur XPT Tumor Marker Quality Controls (TMQC) - Siemens, ARCHITECT BNP Calibrators (China), ARCHITECT BNP Reagents (China), ARCHITECT BNP Reagents, Calibrators and Controls, ARCHITECT BNP-JP Calibrators, ARCHITECT BNP-JP Controls, ARCHITECT BNP-JP Reagents and more
Devices it lists
510(k) clearances
The 510(k) numbers this establishment lists, with the FDA decision on each. The applicant is the company that holds the clearance.
| Decided | 510(k) number | Device | Product code | Decision | Applicant | Source |
|---|---|---|---|---|---|---|
| May 16, 2025 | K242706 | Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio | SET | Substantially Equivalent | Fujirebio Diagnostics,Inc. | accessdata.fda.gov |
| May 4, 2022 | DEN200072 | Lumipulse G ß-Amyloid Ratio (1-42/1-40) | QSE | Unknown | Fujirebio Diagnostics,Inc. | accessdata.fda.gov |
Recalls
Recall events where this establishment is the recalling firm, matched on its FEI.
| Initiated | Event | Class | Status | Product | Reason | Source |
|---|---|---|---|---|---|---|
| December 11, 2025 | 98232 | Class II | Ongoing | Product Name: Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio Model/Catalog Number: CL0073 Software Version: Not Applicable Product Description: Lumipulse G pTau217/-Amyloid 1-42 Plasma Ratio is an in vitro diagnostic (I | Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as hav | accessdata.fda.gov |
| July 29, 2010 | 56427 | Not yet classified | Terminated | MESOMARK Humanitarian Device. Authorized by Federal Law for use as an aid in monitoring of patients diagnosed with mesothelioma. Each kit contains 96 tests. MESOMARK is an enzyme linked immunosorbent assay (ELISA) for th | presence of material attached to the bottom of some wells in places visible to the naked eye, which caused an overestimation of the sample. | accessdata.fda.gov |
Compare with other makers
- All makers of Cytokeratin Fragments 21-1 Eia Kit
- All makers of Calibrators, Drug Specific
- All makers of Cyclosporine
- All makers of Single (Specified) Analyte Controls (Assayed And Unassayed)
- All makers of System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer
- All makers of Calibrator, Secondary
Updated February 5, 2026. Read from openFDA bulk downloads (device registration and listing, 510(k), PMA, recall and enforcement files). CC0 1.0, public domain (openFDA terms of service). The files are joined on FDA identifiers: the 510(k) and PMA numbers a registration lists, and the recalling firm's FEI for recalls. Recall class comes from the FDA enforcement report. The FDA states that openFDA data is unvalidated and is not for decisions about medical care. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.